NCT05984602View on ClinicalTrials.gov

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

January 1, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

Canakinumab

250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle

DRUG

Tislelizumab

300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle

DRUG

Nab-Paclitaxel

125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle

DRUG

Gemcitabine

1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle

Trial Locations (3)

10016

RECRUITING

Ambulatory Care Center, New York

RECRUITING

Clinical Cancer Center, New York

RECRUITING

NYU Langone Ambulatory Care Center East 38th Street, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER